A single infusion that edits a gene directly inside a patient’s liver appears to keep working four years later, according to its developer, Intellia Therapeutics. The treatment now awaits a decision from the US Food and Drug Administration (FDA). If it is approved, it would become the world’s first CRISPR medicine delivered straight into the body rather than applied to cells in a lab.

The therapy is called lonvoguran ziclumeran, or lonvo-z for short. It targets one form of hereditary angioedema, an inherited disorder that causes repeated bouts of painful swelling. These attacks can affect the throat and other parts of the body, and they can be dangerous. Intellia, based in Cambridge, Massachusetts, has asked the FDA for approval, and a decision is expected by 10 March. Chief executive John Leonard told investors on 12 November that approval would make lonvo-z the first CRISPR medicine given in vivo, meaning inside the living body.

Switching off a troublemaking gene

CRISPR-Cas9 is a gene-editing tool that can find a specific stretch of DNA and cut it. Lonvo-z uses this system to disable the gene that makes prekallikrein. This protein is produced in the liver and encourages blood vessels to leak.

The medicine itself is made of tiny fatty particles wrapped around mRNA, the genetic instructions cells use to build proteins. Here, the mRNA carries the recipe for the CRISPR-Cas9 components. Once the particles are infused into the bloodstream, the liver absorbs them, and that is exactly where prekallikrein is made. The whole procedure takes a single day.

Jonathan Bernstein specialises in hereditary angioedema at the University of Cincinnati in Ohio and is one of the investigators on a lonvo-z trial. He says the gene-editing approach could free patients from a lifetime of combining medicines to head off and treat attacks. Of the four-year results, he says: “It’s very reassuring. That’s what you’re supposed to see.”

Why editing inside the body matters

Only one CRISPR therapy currently has FDA approval. Casgevy treats two inherited blood disorders, sickle cell anemia and β-thalassemia, and it works very differently. Doctors first collect a patient’s blood stem cells and send them away to be edited. The edited cells are then infused back into the same person.

Because each dose has to be custom-made, the process takes longer, costs more and is more complicated. Patients must also go through harsh chemotherapy to make space for the edited cells. In vivo approaches like lonvo-z aim to avoid these hurdles by doing the editing inside the body itself.

New kinds of risk

Editing inside the body brings its own safety questions. With cells edited in a lab, there is a chance to check them before they go back into the patient. Once the editing happens in the patient, there is no way to screen out cells that picked up unintended changes elsewhere in the genome or in other organs. Patients could also mount harmful immune reactions to the treatment.

These concerns are not merely hypothetical. Last year, the FDA halted a pair of Intellia’s other in vivo trials when someone taking part developed liver damage and died after receiving a CRISPR treatment. The participant was an older man who had other medical problems. The agency lifted that hold this year after requiring additional safety measures.

What comes next

The latest durability figures come from data released by Intellia itself. If regulators give the go-ahead by March, lonvo-z would mark a shift for gene editing. The technology would move from a custom lab process to a one-day infusion given directly to the patient. For people with hereditary angioedema, Bernstein says, that could mean an alternative to a lifelong routine of medications.

Sources: www.nature.com.

News – Curated by Amanda Scott, Alias Group Creative
Follow her on Bluesky

Blockchain in Healthcare: Real Applications

Blockchain in healthcare refers to the use of distributed ledger technology to secure, manage, and share medical data and processes. Applications include patient record management, prescription tracking, and supply chain authentication, all designed to [...]

Our books are available worldwide!

Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]

GHCE Concept

From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]